Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death

Pediatrics

Volumn 119, Issue 1, 2007, Pages 154-155

  Knight, Matthew ^a  

^a OSFMG Morton Pediatrics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; METHYLPHENIDATE; CENTRAL STIMULANT AGENT;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; DECISION MAKING; HUMAN; HYPERACTIVITY; NOTE; PRIORITY JOURNAL; SUDDEN DEATH; ARTICLE; CHILD;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEATH, SUDDEN, CARDIAC; HUMANS; METHYLPHENIDATE;

EID: 33846913525     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-2467     Document Type: Note

References (6)

1. Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J Am Coll Cardiol. 1985;5(6 suppl):118B-121B
2. Gorman RL. FDA panel recommends black box warning on ADHD stimulant medications. AAP News. 2006;27:16
3. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children With ADHD. Arch Gen Psychiatry. 1999;56:1073-1086
4. Jellinek MS. Of risks and benefits, bicycles and Ritalin. Pediatr News. 2006:27
5. American Academy of Pediatrics, Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics. 2000;105:1158-1170
6. American Academy of Pediatrics, Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the schoolaged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:1033-1044